Replies to post #312285 on Avid Bioservices Inc (CDMO)

[cjgaddy]

Thx/PM: "This same joint PPHM+MSKCC TITLED poster was presented..."

[jakedogman1]

Poster comparisons... SITC 2017 vs SITC 2016

Author differences:

Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma

2017 Poster

Sadna Budhu1, Rachel Giese1, Olivier De Henau1, Roberta Zappasodi1, Luis Felipe Campesato1, Aditi Gupta1, Christopher Barker1, Bruce Freimark2, Jedd D. Wolchok1, Taha Merghoub1
1Memorial Sloan Kettering Cancer Center, New York, NY, USA 2Peregrine Pharmaceuticals, Inc., Tustin, CA, USA

2016 Poster

Sadna Budhu1 , Olivier De Henau 1 , Roberta Zappasodi 1 , Kyle Schlunegger 2 , Bruce Freimark 2 , Jeff Hutchins 2 , Christopher A. Barker 3 , Jedd D. Wolchok 1 and Taha Merghoub 1

Checkpoint blockade | Radiotherapy | Tumor infiltrating lymphocytes (TILs) | Solid tumors

New Authors on Poster https://www.mskcc.org/research-areas/labs/jedd-wolchok

Rachel Giese MD
Tumors can be recognized by the immune system through their ability to make certain proteins that are not present in normal cells, called neoantigens. I am working to identify CD8+ T cells that recognize these neoantigens, in cancer patients using a combinatorial multimer technology. If we can identify relevant neoantigens, we may be able to augment tumor rejection by the immune system. In addition, I am working on a mouse model of oral cavity carcinoma to study the role of inflammation induced by bacteria in the mouth and the to response to immunotherapy.

Luis Felipe Campesato Phd
My aim is to investigate the immunosuppressive network existent in the tumor microenvironment. In particular, my research focuses on exploring the crosstalk between tumor cells and suppressive myeloid cells, and how that interaction affects T cell-mediated immunity. Based on these findings I will develop means to overcome immune suppression and generate more efficient antitumor immunity.

Aditi Gupta
Gupta will study the expression pattern of a protein called TGF beta in melanoma, working to characterize whether inhibiting TGF beta prevents cancer growth. Gupta will be mentored by Memorial Sloan Kettering Cancer Center investigators Dr. Jedd Wolchok, the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation and chief of the Melanoma and Immunotherapeutics Service, and Dr. Taha Merghoub, co-director of the Ludwig Collaborative Laboratory and the Swim Across America Laboratory.

https://news.weill.cornell.edu/news/2017/04/five-weill-cornell-medical-students-win-prestigious-howard-hughes-fellowships

[biopharm]

1 Peregrine Pharmaceuticals
2 Epiontis GmbH, Berlin, Germany
3 Precision Medicine, Frederick MD

Very interesting trio I see involved in upcoming Nov presentation ...and one should be very curious of the timing of Precision for Medicine advised by Bird/Bird to buy out Epiontis so the trio becomes a duo....and my question of late to all...

The new knowledge learned that was once for hundreds of years non-obvious....but then when PS Targeting collaborations make one smarter and realize what was once non obvious but after PS Targeting ....is absolutely obvious, THEN patents filed based on that knowledge AFTER PS Targeting Biomarkers are discovered ....should be claimed by Peregrine for IP rights....

....but what about companies bought out due to this knowledge ?? Things become more interesting now and why did Bird/Bird advise Precision for Medicine to buy Epiontis? ...when the trio were in collaborations / research....